Categories
Change Password!
Reset Password!
Letrozole is a strong alternative to Clomiphene citrate for improving follicle maturation in women with PCOS-related subfertility, thus increasing pregnancy chances.
In a recent study, Letrozole (an aromatase inhibitor) has emerged as a useful alternative to Clomiphene citrate for inducing ovulation in females with polycystic ovarian syndrome (PCOS). This study published in the “Pakistan Journal of Health Sciences” aimed to evaluate the rate of mature follicle development following Letrozole treatment.
The interventional study spanning six months, involved 322 women aged 20-40 with infertility lasting over a year, body mass index (BMI) <28, and diagnosed with subfertility due to PCOS. Participants underwent Letrozole treatment, with mature follicle development monitored via transvaginal ultrasound starting on day 10 of treatment. The average age of participants was 32.82 years, with a mean weight of 61.74 kg and height of 1.61 m, resulting in an average BMI of 23.68 kg/m².
Half of the volunteers reported primary infertility, while the other half reported secondary infertility. Notably, after Letrozole use, 237 women (73.6%) displayed mature follicles on ultrasound. Letrozole effectively promoted follicle maturation in women with PCOS-related subfertility, increasing the chances of pregnancy. Given its favorable outcomes and minimal side effects, Letrozole appears to be a valuable substitute for those resistant to Clomiphene citrate.
Pakistan Journal of Health Sciences
Impact of Letrozole on Mature Follicle Rate in Treatment of Subfertility Due to Polycystic Ovarian Syndrome
Mehvish Javeri et. al.
Comments (0)